CLINICAL TRIALS PROFILE FOR TISSEEL
✉ Email this page to a colleague
All Clinical Trials for TISSEEL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00028951 ↗ | Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva | Completed | National Cancer Institute (NCI) | Phase 3 | 2003-01-01 | RATIONALE: Fibrin sealant may decrease lymphedema following surgery to remove lymph nodes in the groin by helping to seal the lymphatic vessels. It is not yet known if fibrin sealant is effective in decreasing lymphedema following surgery to remove lymph nodes. PURPOSE: Randomized phase III trial to determine the effectiveness of fibrin sealant in reducing lymphedema following surgical removal of lymph nodes in patients who have cancer of the vulva. |
| NCT00028951 ↗ | Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva | Completed | Gynecologic Oncology Group | Phase 3 | 2003-01-01 | RATIONALE: Fibrin sealant may decrease lymphedema following surgery to remove lymph nodes in the groin by helping to seal the lymphatic vessels. It is not yet known if fibrin sealant is effective in decreasing lymphedema following surgery to remove lymph nodes. PURPOSE: Randomized phase III trial to determine the effectiveness of fibrin sealant in reducing lymphedema following surgical removal of lymph nodes in patients who have cancer of the vulva. |
| NCT00155402 ↗ | The Application of Fibrin Glue in Ocular Surface Diseases | Withdrawn | National Taiwan University Hospital | Phase 1 | 2005-04-01 | This clinical trial tries to use tissue fibrin glues (Tisseel) to treat various ocular surface diseases or surgeries, which includes pterygium surgery, corneal melting/perforation, Gunderson's flap, conjunctival laceration, and muscle/clinical/filtering surgery. |
| NCT00161733 ↗ | Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery | Completed | Baxter Healthcare Corporation | Phase 3 | 2002-09-01 | The objective of this study is to demonstrate equivalent hemostatic efficacy and safety between FS VH S/D and TISSEEL VH fibrin sealant in subjects undergoing cardiac surgery requiring cardiopulmonary bypass. If bleeding is still present after conventional surgical methods to achieve hemostasis have been applied FS VH S/D or Tisseel VH are applied. Achievement of hemostasis within 5 minutes is compared between the study groups. |
| NCT00504582 ↗ | Fibrin Melanoma Axillary Node Study in Patients With Melanoma | Completed | M.D. Anderson Cancer Center | N/A | 2002-05-01 | Primary Objective: - To determine whether the use of a fibrin sealant applied to axillary soft tissues following node dissection can result in earlier drain removal. Secondary Objectives: - To determine the postoperative morbidity rate using fibrin sealant following axillary node dissection. - To assess patient-valuation of outcome by performing a cost-benefit analysis using a willingness-to-pay model. - To determine if serum levels, lymphatic fluids level, or cutaneous expression of vascular endothelial growth factor-D (VEGF-D), vascular endothelial growth factor-C (VEGF-C) or their receptor, vascular endothelial growth factor receptor-3 (VEGFR-3) correlates with nodal tumor burden or development of lymphedema in patients with melanoma. |
| NCT00506311 ↗ | Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients | Completed | Bayer | N/A | 2003-02-01 | Primary Objective: 1. To determine whether the use of a fibrin sealant applied to superficial groin soft tissues following node dissection can result in decreased cumulative postoperative drainage, earlier drain removal, and lower incidence of seroma. Secondary Objectives: 1. To determine the postoperative morbidity rate using fibrin sealant following superficial groin dissection. 2. To assess patient-valuation of outcome by performing a cost-benefit analysis using a willingness-to-pay model. 3. To determine if serum levels, lymphatic fluids level, or cutaneous expression of vascular endothelial growth factor-D (VEGF-D), vascular endothelial growth factor-C (VEGF-C) or their receptor, vascular endothelial growth factor receptor-3 (VEGFR-3) correlates with nodal tumor burden or development of lymphedema in patients with melanoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TISSEEL
Condition Name
Clinical Trial Locations for TISSEEL
Trials by Country
Clinical Trial Progress for TISSEEL
Clinical Trial Phase
Clinical Trial Sponsors for TISSEEL
Sponsor Name
